Bakgrunn og aktiviteter
Lege og kreftspesialist. Bistilling som overlege ved Kreftklinikken, St. Olavs Hospital, med ansvar for behandling av lungekreft. Hovedstilling som forsker ved Institutt for Kreftforskning og molekylær medisin, NTNU. Instituttgruppeleder for Instituttgruppe for kreft og pasientnær forskning. Driver mest med klinisk lungekreftforskning, men forsker også på helserelatert livskvalitet, kreft hos eldre, kroppssammensetning, pasientinformasjon, og pasientforløp. Har etablert translasjonsforskningsgruppe som forsker liquid biopsies hos kreftpasienter.
Utdanning:
- Cand. med., Universitetet i Bergen, 1994
- Spesialist i behandling av kreftsykdommer, St. Olavs Hospital, 2001
- Doktorgrad (PhD i klinisk medisin), NTNU, 2010
Forskningsinteresser:
- Lungekreft
- Eldre og kreft
- ctDNA
Pågående studier:
- Nordic randomized phase II study comparing two schedules of hyperfractionated thoracic radiotherapy in limited disease small-cell lung cancer
- Randomized phase III study comparing maintenance pemetrexed therapy after induction chemotherapy versus pemetrexed at progression in advanced non-small-cell lung cancer
- The prognostic and predictive role of ctDNA-analyses in lung cancer patients who undergo surgery
Vitenskapelig, faglig og kunstnerisk arbeid
Et utvalg av nyere tidsskriftspublikasjoner, kunstneriske produksjoner, bok, inklusiv bokdeler og rapport-del. Se alle publikasjoner i databasen
Tidsskriftspublikasjoner
- (2019) Modifiable factors affecting older patients' quality of life and physical function during cancer treatment. Journal of Geriatric Oncology.
- (2019) Frailty identified by geriatric assessment is associated with poor functioning, high symptom burden and increased risk of physical decline in older cancer patients: Prospective observational study. Palliative Medicine. vol. 33 (3).
- (2019) Autocrine activin A signalling in ovarian cancer cells regulates secretion of interleukin 6, autophagy, and cachexia. Journal of Cachexia, Sarcopenia and Muscle.
- (2018) Cancer patients' knowledge about their disease and treatment before, during and after treatment: a prospective, longitudinal study. BMC Cancer. vol. 18:381.
- (2018) Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016. Lung Cancer. vol. 122.
- (2018) A comparison of CT based measures of skeletal muscle mass and density from the Th4 and L3 levels in patients with advanced non-small-cell lung cancer. European Journal of Clinical Nutrition.
- (2018) Screening for frailty among older patients with cancer using blood biomarkers of inflammation. Journal of Geriatric Oncology.
- (2018) Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: a pooled analysis of two randomized trials. Acta Oncologica. vol. 57 (11).
- (2018) Expression of estrogen receptor-α and survival in advanced-stage non-small cell lung cancer. Anticancer Research. vol. 38 (4).
- (2018) Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement. Anticancer Research. vol. 38 (2).
- (2017) Muscle mass and association to quality of life in non-small cell lung cancer patients. Journal of Cachexia, Sarcopenia and Muscle. vol. 8.
- (2017) Geriatric assessment is superior to oncologists’ clinical judgement in identifying frailty. British Journal of Cancer. vol. 117 (4).
- (2017) Measurement of health-related quality of life during chemotherapy -the importance of timing. Acta Oncologica. vol. 56 (5).
- (2017) Livskvalitet under cellegiftbehandling -betydning av måletidspunkt. Best Practice Onkologi/Hematologi.
- (2017) Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial. Acta Oncologica. vol. 56 (12).
- (2017) Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling. Scientific Reports. vol. 7 (1).
- (2017) Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Non-Small-Cell Lung Cancer. Clinical Lung Cancer. vol. 18 (2).
- (2017) Medical complexity and time to lung cancer treatment - A three-year retrospective chart review. BMC Health Services Research. vol. 17:45.
- (2016) Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer. Annals of Oncology. vol. 27 (2).
- (2016) Oral versus intravenous vinorelbine in advanced NSCLC - a retrospective comparison. Cancer Treatment and Research Communications. vol. 9.